Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia

E. Schneider, K. H. Cowan, H. Bader, S. Toomey, G. N. Schwartz, J. E. Karp, P. J. Burke, S. H. Kaufmann

Research output: Contribution to journalArticle

166 Citations (Scopus)

Abstract

Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to determine relative levels of transcripts for MDR1 and the recently described multidrug resistance-associated protein (MRP) in normal lymphohematopoietic cells and in 62 bone marrow aspirates of newly diagnosed and recurrent acute leukemia. Levels of MRP expression in newly diagnosed AML samples were similar to those observed in normal bone marrow cells (CD34- negative and CD34-positive) and in unselected HL60 human promyelocytic leukemia cells, which were used as an internal control throughout this study. In contrast, samples of AML obtained at the time of relapse contained approximately twofold higher levels of MRP RNA (P < .01). Analysis of paired samples, the first obtained at diagnosis and the second at relapse, from 13 acute myelogenous leukemia (AML) and four acute lymphocytic leukemia (ALL) patients showed that MRP expression was increased at the time of relapse in greater than 80% of patients. In contrast, no consistent changes of MDR1 expression at relapse were observed. These results raise the possibility that increased MRP expression might contribute to leukemic relapse.

Original languageEnglish (US)
Pages (from-to)186-193
Number of pages8
JournalBlood
Volume85
Issue number1
StatePublished - Jan 1 1995

Fingerprint

Multidrug Resistance-Associated Proteins
Leukemia
Genes
Recurrence
Acute Myeloid Leukemia
Bone
Polymerase chain reaction
RNA-Directed DNA Polymerase
Reverse Transcriptase Polymerase Chain Reaction
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow Cells
Bone Marrow
Cells
RNA

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Schneider, E., Cowan, K. H., Bader, H., Toomey, S., Schwartz, G. N., Karp, J. E., ... Kaufmann, S. H. (1995). Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood, 85(1), 186-193.

Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. / Schneider, E.; Cowan, K. H.; Bader, H.; Toomey, S.; Schwartz, G. N.; Karp, J. E.; Burke, P. J.; Kaufmann, S. H.

In: Blood, Vol. 85, No. 1, 01.01.1995, p. 186-193.

Research output: Contribution to journalArticle

Schneider, E, Cowan, KH, Bader, H, Toomey, S, Schwartz, GN, Karp, JE, Burke, PJ & Kaufmann, SH 1995, 'Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia', Blood, vol. 85, no. 1, pp. 186-193.
Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood. 1995 Jan 1;85(1):186-193.
Schneider, E. ; Cowan, K. H. ; Bader, H. ; Toomey, S. ; Schwartz, G. N. ; Karp, J. E. ; Burke, P. J. ; Kaufmann, S. H. / Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. In: Blood. 1995 ; Vol. 85, No. 1. pp. 186-193.
@article{ffe195014c4f47559e40fa643fb705cb,
title = "Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia",
abstract = "Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to determine relative levels of transcripts for MDR1 and the recently described multidrug resistance-associated protein (MRP) in normal lymphohematopoietic cells and in 62 bone marrow aspirates of newly diagnosed and recurrent acute leukemia. Levels of MRP expression in newly diagnosed AML samples were similar to those observed in normal bone marrow cells (CD34- negative and CD34-positive) and in unselected HL60 human promyelocytic leukemia cells, which were used as an internal control throughout this study. In contrast, samples of AML obtained at the time of relapse contained approximately twofold higher levels of MRP RNA (P < .01). Analysis of paired samples, the first obtained at diagnosis and the second at relapse, from 13 acute myelogenous leukemia (AML) and four acute lymphocytic leukemia (ALL) patients showed that MRP expression was increased at the time of relapse in greater than 80{\%} of patients. In contrast, no consistent changes of MDR1 expression at relapse were observed. These results raise the possibility that increased MRP expression might contribute to leukemic relapse.",
author = "E. Schneider and Cowan, {K. H.} and H. Bader and S. Toomey and Schwartz, {G. N.} and Karp, {J. E.} and Burke, {P. J.} and Kaufmann, {S. H.}",
year = "1995",
month = "1",
day = "1",
language = "English (US)",
volume = "85",
pages = "186--193",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia

AU - Schneider, E.

AU - Cowan, K. H.

AU - Bader, H.

AU - Toomey, S.

AU - Schwartz, G. N.

AU - Karp, J. E.

AU - Burke, P. J.

AU - Kaufmann, S. H.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to determine relative levels of transcripts for MDR1 and the recently described multidrug resistance-associated protein (MRP) in normal lymphohematopoietic cells and in 62 bone marrow aspirates of newly diagnosed and recurrent acute leukemia. Levels of MRP expression in newly diagnosed AML samples were similar to those observed in normal bone marrow cells (CD34- negative and CD34-positive) and in unselected HL60 human promyelocytic leukemia cells, which were used as an internal control throughout this study. In contrast, samples of AML obtained at the time of relapse contained approximately twofold higher levels of MRP RNA (P < .01). Analysis of paired samples, the first obtained at diagnosis and the second at relapse, from 13 acute myelogenous leukemia (AML) and four acute lymphocytic leukemia (ALL) patients showed that MRP expression was increased at the time of relapse in greater than 80% of patients. In contrast, no consistent changes of MDR1 expression at relapse were observed. These results raise the possibility that increased MRP expression might contribute to leukemic relapse.

AB - Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was used to determine relative levels of transcripts for MDR1 and the recently described multidrug resistance-associated protein (MRP) in normal lymphohematopoietic cells and in 62 bone marrow aspirates of newly diagnosed and recurrent acute leukemia. Levels of MRP expression in newly diagnosed AML samples were similar to those observed in normal bone marrow cells (CD34- negative and CD34-positive) and in unselected HL60 human promyelocytic leukemia cells, which were used as an internal control throughout this study. In contrast, samples of AML obtained at the time of relapse contained approximately twofold higher levels of MRP RNA (P < .01). Analysis of paired samples, the first obtained at diagnosis and the second at relapse, from 13 acute myelogenous leukemia (AML) and four acute lymphocytic leukemia (ALL) patients showed that MRP expression was increased at the time of relapse in greater than 80% of patients. In contrast, no consistent changes of MDR1 expression at relapse were observed. These results raise the possibility that increased MRP expression might contribute to leukemic relapse.

UR - http://www.scopus.com/inward/record.url?scp=0028794758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028794758&partnerID=8YFLogxK

M3 - Article

C2 - 7528566

AN - SCOPUS:0028794758

VL - 85

SP - 186

EP - 193

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -